This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Avadel Pharmaceuticals 過去の業績
過去 基準チェック /06
Avadel Pharmaceuticalsの収益は年間平均-5.9%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間9.7% 73.3%割合で 増加しています。
主要情報
-5.94%
収益成長率
0.014%
EPS成長率
| Pharmaceuticals 業界の成長 | 5.95% |
| 収益成長率 | 73.27% |
| 株主資本利益率 | -0.28% |
| ネット・マージン | -0.11% |
| 前回の決算情報 | 30 Sep 2025 |
最近の業績更新
Recent updates
ナラティブの更新 • Feb 03
AVDL: Revised Acquisition Terms And CVR Structure Will Shape Future Risk Balance
Analysts lifted their price target on Avadel Pharmaceuticals to $22.50 from $20, citing improved acquisition terms and updated deal expectations as the key reasons for the change. Analyst Commentary Recent research highlights how the evolving acquisition proposals around Avadel Pharmaceuticals are shaping valuation views and risk assessments for investors following the stock.
ナラティブの更新 • Jan 20
AVDL: Alkermes Cash Deal And CVR Structure Will Define Limited Upside
Analysts lifted their fair value estimate for Avadel Pharmaceuticals to $18.50 from $16.00, citing updated acquisition terms, improved contingent value right economics, and revised assumptions around margins and future P/E multiples following recent Street research. Analyst Commentary Recent Street research around Avadel Pharmaceuticals has shifted toward a more balanced and, in several cases, more cautious stance as the Alkermes acquisition framework has taken shape.
ナラティブの更新 • Jan 06
AVDL: Cash Deal Terms And CVR Outcome Will Shape Future Returns
Analysts kept their fair value estimate for Avadel Pharmaceuticals at $23.00 per share while adjusting key assumptions, citing the updated Alkermes and Lundbeck proposals and evolving views on Lumryz royalties and contingent value right terms as the main drivers of the new target range around recent Street marks near $20.00 to $22.50. Analyst Commentary Recent Street research around Avadel Pharmaceuticals has centered on the competing acquisition proposals from Alkermes and Lundbeck, as well as the value of Lumryz royalties and the contingent value right, or CVR, tied to potential future approvals.ナラティブの更新 • Dec 19
AVDL: Cash Deal And Contingent Payout Will Shape Future Returns
Analysts have trimmed their price target on Avadel Pharmaceuticals to $23.00 from about $31.47, reflecting updated assumptions for slightly higher risk, stronger revenue growth, and sharply improved profitability metrics in light of the evolving Alkermes acquisition dynamics and Lumryz-driven cash flow profile. Analyst Commentary Across recent research notes, bullish analysts acknowledge that headline price targets for Avadel are now clustered in the high teens to low twenties, reflecting the proposed acquisition by Alkermes and the embedded value of the contingent value right tied to Lumryz milestones.ナラティブの更新 • Dec 05
AVDL: Acquisition And CVR Milestones Will Define Balanced Risk Reward Profile
Analysts have nudged our fair value estimate for Avadel Pharmaceuticals slightly lower, from $21.06 to $20.94 per share, as they balance modestly reduced long term multiple assumptions with the evolving acquisition landscape and contingent value right dynamics highlighted in recent research. Analyst Commentary Street research reflects a more balanced, wait and see stance on Avadel as the Alkermes transaction and competing interest from Lundbeck reshape the risk reward profile.ナラティブの更新 • Nov 21
AVDL: Competing Acquisition Proposals Will Shape Outcomes Amid Industry Uncertainty
Analysts have raised their fair value estimate for Avadel Pharmaceuticals from $19.13 to $21.06 per share. They cite improving profit margins and stronger near-term acquisition prospects as key factors behind the upward revision.ナラティブの更新 • Nov 05
AVDL: Future Acquisition to Reshape Sleep Disorder Market Amid Shifting Competitive Risks
Analysts have lowered their price target for Avadel Pharmaceuticals from $20.90 to $19.13 per share. This change reflects recent acquisition agreements and shifting perspectives on the company’s long-term growth prospects.Seeking Alpha • Oct 23
Avadel Settles With Jazz Pharmaceuticals, Gets Acquired By Alkermes
Summary Avadel Pharmaceuticals plc settled all disputes with Jazz Pharmaceuticals plc, paving the way for its acquisition by Alkermes plc for up to $20/share. The settlement grants AVDL $90 million in cash, freedom to operate globally with Lumryz, and eliminates a significant legal overhang. ALKS benefits from immediate earnings accretion, revenue diversification, and a strengthened position in sleep disorder treatments with Lumryz. JAZZ avoids billion-dollar-plus damages, secures modest royalties on Lumryz, and delays competition in idiopathic hypersomnia until 2028. Read the full article on Seeking Alphaナラティブの更新 • Oct 22
Analysts Adjust Avadel Pharmaceuticals Price Target Amid Acquisition and Ongoing Market Developments
Analysts have lowered their price target for Avadel Pharmaceuticals to $20 from previous higher levels. They cite the pending acquisition by Alkermes at $18.50 per share, plus a potential $1.50 contingent cash right, as the primary driver behind the adjustment.ナラティブの更新 • Oct 08
Rising Awareness Of Sleep Disorders Will Drive Future Demand
Analysts have raised their price target for Avadel Pharmaceuticals from $20.30 to $20.90, citing continued commercial momentum for Lumryz. However, they note this optimism is tempered by competitive and market uncertainties.ナラティブの更新 • Sep 23
Rising Awareness Of Sleep Disorders Will Drive Future Demand
Analysts marginally raised Avadel Pharmaceuticals’ price target to $20.30, citing strong commercial execution and growing Lumryz adoption, while noting competitive risks may limit upside. Analyst Commentary Bullish analysts highlight that commercial investments are delivering tangible benefits, evidenced by improved persistency and an expanding number of reimbursed Lumryz patients.ナラティブの更新 • Sep 08
Rising Awareness Of Sleep Disorders Will Drive Future Demand
Analysts have raised Avadel Pharmaceuticals' fair value target from $19.00 to $20.20, citing improved commercial execution for Lumryz and pipeline expansion opportunities, though some caution over competition and valuation is noted. Analyst Commentary Bullish analysts highlight commercial execution gains, with improved persistency trends and increasing reimbursed Lumryz patient counts driving revenue upside.ナラティブの更新 • Aug 24
Rising Awareness Of Sleep Disorders Will Drive Future Demand
The upward revision in Avadel Pharmaceuticals' consensus price target reflects improved revenue growth expectations and a modest increase in future P/E, resulting in a new fair value estimate of $19.12. What's in the News Avadel Pharmaceuticals raised full-year 2025 revenue guidance to $265–$275 million and projected Q3 2025 net product revenue of $71–$75 million.分析記事 • Aug 10
Results: Avadel Pharmaceuticals plc Exceeded Expectations And The Consensus Has Updated Its Estimates
NasdaqGM:AVDL 1 Year Share Price vs Fair Value Explore Avadel Pharmaceuticals's Fair Values from the Community and...ナラティブの更新 • Aug 09
Rising Awareness Of Sleep Disorders Will Drive Future Demand
Despite a notable reduction in consensus revenue growth forecasts, the analyst price target for Avadel Pharmaceuticals has increased slightly to $18.00. What's in the News Avadel Pharmaceuticals raised full-year 2025 revenue guidance to $265–$275 million and expects Q3 net product revenue of $71–$75 million.分析記事 • Aug 02
A Piece Of The Puzzle Missing From Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 26% Share Price Climb
Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) shareholders have had their patience rewarded with a 26% share price jump in...分析記事 • Jun 10
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
新しいナラティブ • May 04
LUMRYZ And REVITALYZ Trials Will Unlock Future Value
LUMRYZ's strong market penetration and $1 billion opportunity hint at future revenue growth, with competitive advantage over peers.分析記事 • May 04
Market Participants Recognise Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Revenues Pushing Shares 28% Higher
Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • Feb 11
Avadel Pharmaceuticals: Moving To A Speculative Buy
Summary Avadel Pharmaceuticals' primary asset, LUMRYZ, treats narcolepsy and is in Phase 3 trials for Idiopathic Hypersomnia, with significant revenue growth potential. Recent news includes the resignation of the Chief Commercial Officer, strong Q4 revenue growth, and a push from ASL Strategic Value Fund for strategic alternatives. Analysts are universally positive, with multiple Buy ratings and price targets ranging from $12 to $22, despite some downward revisions. Avadel has a solid balance sheet, no long-term debt, and insiders are accumulating shares, making it a speculative buy with potential for a profitable buyout. Read the full article on Seeking Alpha分析記事 • Feb 07
The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 26%
Unfortunately for some shareholders, the Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) share price has dived 26% in the...分析記事 • Jan 13
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Dec 01
The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27%
The Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Nov 22
Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky
Summary Avadel Pharmaceuticals plc's Lumryz, a superior alternative to Jazz's Xyrem, faces legal hurdles and market challenges despite winning key lawsuits and FDA approval. Financially, Avadel has a market cap of $1.04bn, $65.8mn cash, and increasing revenue, but high SG&A expenses and a weak cash position. Jazz's legal actions and the shrinking narcolepsy market limit Lumryz's revenue potential, raising concerns about Avadel's long-term viability. Despite supporting Avadel as a company, I recommend avoiding AVDL stock due to significant risks and financial challenges. Read the full article on Seeking Alpha分析記事 • Oct 16
Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable
When you see that almost half of the companies in the Pharmaceuticals industry in the United States have price-to-sales...分析記事 • Sep 10
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Sep 03
Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Summary Avadel shareholders have enjoyed impressive gains of approximately 77% since my last article, reflecting positive developments in the company's performance. The article provides a comprehensive review of Avadel's progress and how it is faring against Jazz Pharmaceuticals in the oxybate market. Despite its lack of a conventional pipeline, the peak sales potential of LUMRYZ in its approved indication supports a speculative Buy rating for Avadel stock. Read the full article on Seeking AlphaSeeking Alpha • Jun 16
Avadel Pharmaceuticals: Inflection Point Ahead
Summary Avadel Pharmaceuticals is a small-cap biopharma company headquartered in Dublin, Ireland. The company's primary asset is LUMRYZ, which has the potential to be a 'best of breed' compound in a large market. Currently, Avadel is locked in a pivotal litigation battle with Jazz Pharmaceuticals, which it looks more and more likely to prevail. This sets up a potential key inflection point for the company and its shareholders. An updated analysis around Avadel Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Apr 02
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Summary Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a more patient-friendly dosing schedule and improving compliance and patient outcomes. Legal developments, including a favorable jury ruling on patent litigation, reduce legal overhang and instill investor confidence in Avadel's ability to navigate challenges. We maintain a buy rating moving into 2024. Read the full article on Seeking AlphaSeeking Alpha • Mar 05
Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Summary Avadel's stock rose 51% post-buy recommendation, buoyed by Q4 earnings and a favorable royalty rate judgment versus Jazz Pharmaceuticals. Lumryz's market penetration and unique once-nightly dosing advantage are driving optimistic revenue forecasts and operational breakeven projections. A court ruling on the patent dispute awarded Avadel a manageable 3.5% royalty to Jazz, significantly less than the feared 27%. Recommends buying AVDL due to its strategic market position, financial health, and recent legal victory, despite high cash burn and ongoing litigation risks. Read the full article on Seeking AlphaSeeking Alpha • Jan 28
Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Summary Avadel Pharmaceuticals has made good progress with the launch of Lumryz, enrolling 1,900 patients and generating $19 million in Q4 net sales. Legal risks from competitor Jazz Pharmaceuticals remain a concern, with ongoing litigation and the potential for Lumryz to be pulled from the market. Lumryz can capture a significant portion of the narcolepsy market and expand into idiopathic hypersomnia. Risk-reward looks favorable for the long side, although the tail legal risk should not be neglected, even if Jazz's attempts look desperate. Read the full article on Seeking Alpha分析記事 • Jan 16
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Jan 11
Avadel May Continue To Outperform With Positive Launch Momentum
Summary Avadel Pharma's launch of its product LUMRYZ is expected to drive the company's stock performance. LUMRYZ appears to have momentum and is differentiated from current narcolepsy treatments. The potential revenue for Avadel from LUMRYZ could ultimately range from $500 million to $2 billion, depending on market share and expansion into new indications. If things continue to go well, that might drive the share price beyond current levels on a multi-year view, but execution risks do remain. Read the full article on Seeking Alpha分析記事 • Sep 22
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...収支内訳
収支内訳
Avadel Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 25 | 249 | 0 | 197 | 40 |
| 30 Jun 25 | 221 | -3 | 185 | 17 |
| 31 Mar 25 | 194 | -26 | 178 | 16 |
| 31 Dec 24 | 169 | -49 | 181 | 15 |
| 30 Sep 24 | 138 | -73 | 172 | 13 |
| 30 Jun 24 | 95 | -106 | 171 | 12 |
| 31 Mar 24 | 55 | -157 | 176 | 12 |
| 31 Dec 23 | 28 | -160 | 152 | 13 |
| 30 Sep 23 | 9 | -159 | 127 | 17 |
| 30 Jun 23 | 1 | -143 | 102 | 17 |
| 31 Mar 23 | 0 | -142 | 77 | 18 |
| 31 Dec 22 | 0 | -137 | 75 | 21 |
| 30 Sep 22 | 0 | -132 | 79 | 17 |
| 30 Jun 22 | 0 | -134 | 86 | 18 |
| 31 Mar 22 | 0 | -90 | 79 | 20 |
| 31 Dec 21 | 0 | -77 | 68 | 17 |
| 30 Sep 21 | 0 | -66 | 56 | 20 |
| 30 Jun 21 | 0 | -56 | 44 | 21 |
| 31 Mar 21 | 10 | -6 | 36 | 19 |
| 31 Dec 20 | 22 | 7 | 32 | 20 |
| 30 Sep 20 | 33 | 16 | 31 | 23 |
| 30 Jun 20 | 48 | 18 | 28 | 25 |
| 31 Mar 20 | 55 | -21 | 28 | 31 |
| 31 Dec 19 | 59 | -33 | 30 | 33 |
| 30 Sep 19 | 69 | -94 | 46 | 31 |
| 30 Jun 19 | 75 | -101 | 65 | 35 |
| 31 Mar 19 | 86 | -96 | 86 | 37 |
| 31 Dec 18 | 103 | -95 | 100 | 39 |
| 30 Sep 18 | 117 | -40 | 101 | 66 |
| 30 Jun 18 | 137 | -2 | 88 | 54 |
| 31 Mar 18 | 154 | 30 | 73 | 42 |
| 31 Dec 17 | 173 | 68 | 59 | 33 |
| 30 Sep 17 | 182 | 81 | 46 | 0 |
| 30 Jun 17 | 174 | 40 | 48 | 0 |
| 31 Mar 17 | 167 | -9 | 47 | 0 |
| 31 Dec 16 | 150 | -41 | 45 | 34 |
| 30 Sep 16 | 152 | 28 | 40 | 0 |
| 30 Jun 16 | 167 | 19 | 32 | 0 |
| 31 Mar 16 | 177 | 23 | 27 | 0 |
| 31 Dec 15 | 173 | 42 | 22 | 0 |
| 30 Sep 15 | 127 | -64 | 19 | 0 |
| 30 Jun 15 | 87 | -46 | 18 | 0 |
| 31 Mar 15 | 43 | -49 | 17 | 0 |
質の高い収益: AVDLは現在利益が出ていません。
利益率の向上: AVDLは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: AVDLは利益が出ておらず、過去 5 年間で損失は年間5.9%の割合で増加しています。
成長の加速: AVDLの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: AVDLは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。
株主資本利益率
高いROE: AVDLは現在利益が出ていないため、自己資本利益率 ( -0.28% ) はマイナスです。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/02/14 05:46 |
| 終値 | 2026/02/11 00:00 |
| 収益 | 2025/09/30 |
| 年間収益 | 2024/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Avadel Pharmaceuticals plc 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| James Molloy | Brean Capital Historical (Janney Montgomery) |
| Jason Butler | Citizens JMP Securities, LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |